BiotechTube

MK-1775 and carboplatin

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Epithelial Ovarian Cancer

Conditions

Epithelial Ovarian Cancer

Trial Timeline

Jul 1, 2010 → Apr 1, 2023

NCT ID
NCT01164995

About MK-1775 and carboplatin

MK-1775 and carboplatin is a phase 2 stage product being developed by Merck for Epithelial Ovarian Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01164995. Target conditions include Epithelial Ovarian Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01164995Phase 2Completed

Competing Products

20 competing products in Epithelial Ovarian Cancer

See all competitors
ProductCompanyStageHype Score
LY2228820 + Carboplatin + Placebo + GemcitabineEli LillyPhase 1/2
41
gemcitabine + carboplatin + paclitaxelEli LillyPhase 2
52
PemetrexedEli LillyPhase 2
52
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solutionSanten PharmaceuticalPhase 2
52
Mirvetuximab Soravtansine + Paclitaxel + Topotecan + Pegylated liposomal doxorubicinAbbViePhase 3
77
Carboplatin + Mirvetuximab Soravtansine + BevacizumabAbbViePhase 2
52
Mirvetuximab SoravtansineAbbViePhase 2
52
AZD5335 + Mirvetuximab Soravtansine (MIRV) + Paclitaxel + Pegylated liposomal Doxorubicin (PLD) + TopotecanAstraZenecaPhase 3
77
AvelumabAstraZenecaPhase 2
52
Active Comparator: Olaparib tablets + PlaceboAstraZenecaPhase 3
77
Olaparib + carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weeklyAstraZenecaPhase 2
52
Olaparib + BevacizumabAstraZenecaApproved
85
Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-concomitant) + Comparator: Adacel™MerckPhase 3
77
PembrolizumabMerckPhase 2
52
GardasilMerckPhase 1
33
NG-350A plus PembrolizumabMerckPhase 1
33
Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF) + Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF) + Comparator: REPEVAX™ (Concomitant) + Comparator: REPEVAX™ (Non-Concomitant)MerckPhase 3
77
V501MerckPhase 3
77
9-valent HPV vaccinationMerckPhase 2
52
Human Papillomavirus vaccineMerckPhase 2
52

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85